Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPROSTADIL vs AMNESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Treatment of erectile dysfunction (intracavernosal injection or urethral suppository),Palliative therapy to maintain patency of ductus arteriosus in neonates with congenital heart defects pending surgery (intravenous infusion)
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Primarily metabolized via oxidation in the lungs, liver, and kidneys. Approximately 80% inactivated by 15-hydroxy dehydrogenase enzyme on first pass through the lungs.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
80-90% bound to albumin.
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
0.3-0.4 L/kg (large, extensive tissue distribution).
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
IV: 100%; intracavernosal: nearly complete; intra-arterial: high first-pass lung metabolism limits systemic bioavailability.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
No specific GFR-based dose modifications established; use with caution in renal impairment due to potential for hypotension.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
No specific Child-Pugh based dose modifications established; use with caution in hepatic impairment due to altered metabolism.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
For patent ductus arteriosus: initial IV infusion 0.05-0.1 mcg/kg/min; titrate to response; for erectile dysfunction: not typically used in pediatric patients.
Not indicated for pediatric use; safety and efficacy not established
Start at lower end of dosing range (e.g., initial IV bolus 20 mcg) due to increased sensitivity and comorbidity; monitor blood pressure closely.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
None.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Risk of priapism (prolonged erection >4 hours) requiring immediate medical attention,Risk of penile fibrosis or angulation with long-term use,Use with caution in patients with bleeding disorders or on anticoagulants due to bleeding risk,Do not use in neonates with respiratory distress syndrome or persistent fetal circulation,Monitor blood pressure during intravenous use due to hypotension risk
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Hypersensitivity to alprostadil,Conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia),Penile implant or anatomical penis deformity (for erectile dysfunction formulations),Neonates with persistent fetal circulation or respiratory distress syndrome (for intravenous formulation),In women who are pregnant or breastfeeding (not indicated)
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
No known food interactions. Grapefruit may increase levels via CYP3A4 inhibition, but clinical significance is low for topical/intracavernosal use.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embryotoxicity. Avoid in pregnancy unless no safer alternative.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
No data on excretion in human milk; M/P ratio unknown. Due to short half-life and local administration, systemic absorption minimal. Use with caution in breastfeeding.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
No established dosing in pregnancy; contraindicated in pregnant women. No dose adjustment data available for pregnant populations.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
Alprostadil causes vasodilation via c AMP increase; watch for hypotension and priapism. For erectile dysfunction, inject into corpus cavernosum, not dorsal vein. For patent ductus arteriosus, monitor respiratory drive as apnea is common in neonates.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Seek immediate medical help if erection lasts more than 4 hours.,Do not use if you have a penile implant or conditions like sickle cell disease.,Avoid driving until you know how this medication affects you.,For injection, rotate injection sites and use within 24hrs of opening vial.,Report any signs of infection at injection site.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Concomitant administration of Alprostadil, a vasodilator, and Aminosalicylic acid, a salicylate, may produce additive antiplatelet effects, increasing the risk of bleeding. Alprostadil inhibits platelet aggregation via cAMP elevation, while Aminosalicylic acid inhibits cyclooxygenase, reducing thromboxane A2 synthesis. Clinically, this may result in prolonged bleeding time, easy bruising, or hemorrhage, especially in patients with underlying coagulopathies or those on other anticoagulants."
"Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Alprostadil, a synthetic prostaglandin E1 analog, exerts its therapeutic effects through vasodilation and inhibition of platelet aggregation. The concurrent use of loxoprofen may attenuate the pharmacological activity of alprostadil by diminishing prostaglandin-mediated responses, potentially leading to reduced efficacy in conditions such as erectile dysfunction or peripheral vascular disease."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPROSTADIL vs AMNESTROGEN, answered by our medical review team.
ALPROSTADIL is a Prostaglandin Analog that works by Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.. AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPROSTADIL and AMNESTROGEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPROSTADIL is: Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.. The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPROSTADIL and AMNESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPROSTADIL is classified as Category C. Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embry. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.